Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2011 | 12-2010 | 09-2010 | 06-2010 | 03-2010 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 158,745 | 179,160 | 137,433 | 219,077 | 222,199 |
| Receivables | 215,304 | 192,972 | 216,740 | 218,695 | 219,676 |
| Inventories | 97,594 | 100,297 | 100,759 | 96,571 | 97,578 |
| Other current assets | 88,941 | 80,465 | 72,365 | 73,705 | 74,288 |
| TOTAL | $560,584 | $552,894 | $527,297 | $608,048 | $613,741 |
| Non-Current Assets | |||||
| PPE Net | 753,612 | 752,657 | 838,559 | 837,580 | 848,322 |
| Intangibles | 321,009 | 319,674 | 644,775 | 644,610 | 656,532 |
| Other Non-Current Assets | 109,415 | 108,148 | 69,642 | 66,399 | 68,276 |
| TOTAL | $1,184,036 | $1,180,479 | $1,552,976 | $1,548,589 | $1,573,130 |
| Total Assets | $1,744,620 | $1,733,373 | $2,080,273 | $2,156,637 | $2,186,871 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 95,527 | 30,582 | 17,816 | 26,774 | 36,343 |
| Accounts payable and accrued liabilities | 33,379 | 30,627 | 33,067 | 29,681 | 33,508 |
| Accrued Expenses | 105,300 | 108,287 | 108,631 | 108,785 | 92,781 |
| Other current liabilities | 14,770 | 20,095 | 15,720 | 19,169 | 16,773 |
| TOTAL | $307,808 | $259,780 | $237,379 | $246,060 | $247,218 |
| Non-Current Liabilities | |||||
| Long Term Debt | 761,293 | 670,270 | 701,075 | 409,441 | 437,911 |
| Deferred Revenues | 58,832 | 66,905 | 62,145 | 61,651 | 67,813 |
| Other Non-Current Liabilities | 111,091 | 119,010 | 103,944 | 107,478 | 118,436 |
| TOTAL | $872,481 | $784,866 | $804,726 | $516,560 | $555,965 |
| Total Liabilities | $1,180,289 | $1,044,646 | $1,042,105 | $762,620 | $803,183 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 51,658 | 56,478 | 57,720 | 66,259 | 66,191 |
| Common Shares | 780 | 775 | 775 | 776 | 775 |
| Retained earnings | -543,827 | -575,162 | -231,598 | -206,657 | -221,111 |
| Other shareholders' equity | 43,735 | 35,240 | 33,925 | 17,257 | 30,781 |
| TOTAL | $564,331 | $688,727 | $1,038,168 | $1,394,017 | $1,383,688 |
| Total Liabilities And Equity | $1,744,620 | $1,733,373 | $2,080,273 | $2,156,637 | $2,186,871 |